Table 3.

Association of novel variant in SP6 and in 8q24 intergenic regions with risk of aggressive prostate cancer, non-aggressive prostate cancer and overall prostate cancer.

Marker	Locus/Nearest gene	EAF Controls	Overall prostate cancer	High Gleason score disease (≥8)	Low Gleason score disease (≤6)	Aggressivea	Non-aggressiveb
			OR (95% CI, p), EAF
		n = 2400	n = 2738	n = 368	n = 1320	n = 1019	n = 804
rs2074187 A/Cc	17q21/SP6	0.042	1.66 (1.38–1.98, 3.752E−5), 0.065	2.09 (1.53–2.87, 0.000005), 0.082	1.50 (1.20–1.87, 0.0004), 0.060	1.89 (1.50–2.37, 4.738E−8), 0.074	1.43 (1.10–1.86, 0.008), 0.058
rs79012498 G/Ac	8q24/PRNCR1-CASC19	0.044	1.81 (1.53–2.15, 4.26E−8), 0.076	2.14 (1.57–2.91, 0.000001), 0.084	1.76 (1.43–2.17, 1.215E−7), 0.073	2.10 (1.69–2.61, 2.851E−11), 0.084	1.57 (1.22–2.01, 0.0005), 0.065

Bold entries show most significant ORs with aggressive clinical variables.

Case-control analyses.

^aAggressive prostate cancer is defined as PSA at diagnosis >20 ng/mL or Gleason Score ≥8 or T3/T4 or N1 or M1 or PCM.

^bNon-aggressive prostate cancer is defined as PSA at diagnosis ≤20 ng/mL and Gleason Score ≤6 and not T3/T4 and not N1 and not M1 and not PCM.

^cEffect allele/Other allele.